Evidence map›Paper›PMID 38463993›Full record

ArticlebioRxiv : the preprint server for biology2024

SUMO Promotes DNA Repair Protein Collaboration to Support Alterative Telomere Lengthening in the Absence of PML.

Rongwei Zhao, Meng Xu, Anne R Wondisford, Rachel M Lackner, Jayme Salsman, Graham Dellaire, David M Chenoweth, Roderick J O'Sullivan, Xiaolan Zhao, Huaiying Zhang

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Rongwei ZhaoDepartment of Biology, Carnegie Mellon University, Pittsburgh, PA 15213, USA.
Meng XuDepartment of Biology, Carnegie Mellon University, Pittsburgh, PA 15213, USA.
Anne R WondisfordDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Rachel M LacknerDepartment of Chemistry, University of Pennsylvania, Philadelphia, PA 19014 , USA.
Jayme SalsmanDepartment of Pathology, Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada.
Graham DellaireDepartment of Pathology, Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada.ORCID 0000-0002-3466-6316
David M ChenowethDepartment of Chemistry, University of Pennsylvania, Philadelphia, PA 19014 , USA.
Roderick J O'SullivanDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Xiaolan ZhaoMolecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0002-8302-6905
Huaiying ZhangDepartment of Biology, Carnegie Mellon University, Pittsburgh, PA 15213, USA.ORCID 0000-0002-1784-2664
Carnegie Mellon University · USDalhousie University · CAUniversity of Pennsylvania · USUPMC Hillman Cancer Center · USMemorial Sloan Kettering Cancer Center · US

Funding

Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolismR01CA207209 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Roderick O'Sullivan · 2016 to 2026
$3.6M
Regulation of genome replication, recombination, and stress responseR35GM145260 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI Xiaolan Zhao · 2022 to 2026
$3.6M
Phase separation-induced nuclear organization in ALT CancerU01CA260851 · NCI · CARNEGIE-MELLON UNIVERSITY · PI ZHANG, HUAIYING · 2020 to 2024
$2.6M
Predoctoral Training in Pharmacological Sciences (Resubmission)T32GM133332 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Tija C. Jacob, Francisco Jose Schopfer · 2020 to 2026
$1.8M
Targeting Nucleic Acid Junctions with Small MoleculesR01GM118510 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI CHENOWETH, DAVID MICHAEL · 2016 to 2020
$1.6M
Understanding the impact of DNA ADP-ribosylation on telomere function in cancer cellsF30CA278287 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WONDISFORD, ANNE · 2023 to 2025
$107k
NCI NIH HHS F30 CA278287NCI NIH HHS R01 CA207209NCI NIH HHS U01 CA260851NIGMS NIH HHS R01 GM118510NIGMS NIH HHS R35 GM145260NIGMS NIH HHS T32 GM133332
6 · The paper itself

Abstract

Alternative lengthening of telomeres (ALT) pathway maintains telomeres in a significant fraction of cancers associated with poor clinical outcomes. A better understanding of ALT mechanisms can provide a basis for developing new treatment strategies for ALT cancers. SUMO modification of telomere proteins plays a critical role in the formation of ALT telomere-associated PML bodies (APBs), where telomeres are clustered and DNA repair proteins are enriched to promote homology-directed telomere DNA synthesis in ALT. However, whether and how SUMO contributes to ALT beyond APB formation remains elusive. Here, we report that SUMO promotes collaboration among DNA repair proteins to achieve APB-independent telomere maintenance. By using ALT cancer cells with PML protein knocked out and thus devoid of APBs, we show that sumoylation is required for manifesting ALT features, including telomere clustering and telomeric DNA synthesis, independent of PML and APBs. Further, small molecule-induced telomere targeting of SUMO produces signatures of phase separation and ALT features in PML null cells in a manner depending on both sumoylation and SUMO interaction with SUMO interaction motifs (SIMs). Mechanistically, SUMO-induced effects are linked to the enrichment of DNA repair proteins, including Rad52, Rad51AP1, and BLM, to the SUMO-containing telomere foci. Finally, we find that Rad52 can undergo phase separation, enrich SUMO on telomeres, and promote telomere DNA synthesis in collaboration with the BLM helicase in a SUMO-dependent manner. Collectively, our findings suggest that, in addition to forming APBs, SUMO also promotes collaboration among DNA repair proteins to support telomere maintenance in ALT cells. Given the promising effects of sumoylation inhibitors in cancer treatment, our findings suggest their potential use in perturbing telomere maintenance in ALT cancer cells.

Identifiers

PMID38463993
PMCPMC10925274
OpenAlexW4392354341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.